Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Geisen, Will R., Berger, Justin, Schwartz, Chelsea, Reddy, Abhimanyu, Rai, Balaj, Wadih, George, Peck, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507983/
https://www.ncbi.nlm.nih.gov/pubmed/32983888
http://dx.doi.org/10.1016/j.idcr.2020.e00962
Descripción
Sumario:The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.

Ejemplares similares